Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond

Jagdeep S. S. Singh, Chim C. Lang (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)


    Heart failure remains a major concern across the globe as life expectancies and delivery of health care continue to improve. There has been a dearth of new developments in heart failure therapies in the last decade until last year, with the release of the results from the PARADIGM-HF Trial heralding the arrival of a promising new class of drug, ie, the angiotensin receptor-neprilysin inhibitor. In this review, we discuss the evolution of our incremental understanding of the neurohormonal mechanisms involved in the pathophysiology of heart failure, which has led to our success in modulating its various pathways. We start by examining the renin-angiotensin-aldosterone system, followed by the challenges of modulating the natriuretic peptide system. We then delve deeper into the pharmacology and mechanisms by which angiotensin receptor-neprilysin inhibitors achieve their significant cardiovascular benefits. Finally, we also consider the potential application of this new class of drug in other areas, such as heart failure with preserved ejection fraction, hypertension, patients with renal impairment, and following myocardial infarction.

    Original languageEnglish
    Pages (from-to)283-295
    Number of pages13
    JournalVascular Health and Risk Management
    Publication statusPublished - 2015


    • Angiotensin receptor-neprilysin inhibitor
    • Candoxatril
    • Heart failure
    • Heart failure with preserved ejection fraction
    • Hypertension
    • Myocardial infarction
    • Nesiritide
    • Omapatrilat
    • Renal impairment

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine
    • Pharmacology (medical)
    • Public Health, Environmental and Occupational Health
    • Hematology
    • Endocrinology, Diabetes and Metabolism


    Dive into the research topics of 'Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond'. Together they form a unique fingerprint.

    Cite this